NCL Method ITA-18
Human Leukocyte Proliferation Assay (HuLa)
Listed in Datasets | publication by group NCL Protocols
Version 2.0 - published on 09 Jul 2020 doi:10.17917/3429-7641 - cite this Last public release: 2.0b
Licensed under these terms
Description
Immunosuppression is a common reason for drug withdrawal from the market. The traditional immune function test used to estimate materials’ immunosuppression is T cell dependent antibody response (TDAR). This method involves a 28 day, in vivo, study evaluating animal antibody titers to a known antigen (KLH) with and without challenge. Due to the limited quantities of novel drug candidates, an in vitro method called Human Leukocyte activation (HuLa) has been developed as a substitute to the traditional TDAR assay in early preclinical development. The method presented herein is based on the HuLa assay originally developed by Mark Collinge et al at Pfizer (1). The protocol presented in this document has been adapted for use with engineered nanomaterials.
Content List
- NCL_Method_ITA-18_June2020.pdf(PDF | 429 KB)
Cite this work
Researchers should cite this work as follows:
- Timothy Potter, Edward Cedrone, Barry Neun, Marina Dobrovolskaia (2020). NCL Method ITA-18. (Version 2.0). NCI Hub. doi:10.17917/3429-7641
Tags
NCL Protocols
This publication belongs to the NCL Protocols group.
When watching a publication, you will be notified when a new version is released.